Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Prostatic Neoplasms 2Neoplasms 1Mesothelioma, Malignant 1Lymphatic Metastasis 1Kidney Neoplasms 1Hemangioma, Capillary 1Head and Neck Carcinoma 1Cerebral Hemorrhage 1Brain Neoplasms 1Bone Neoplasms 1Arteriovenous Malformations 1

Interventions

Cisplatin 57Pemetrexed 46pembrolizumab 18Nivolumab 15Carboplatin 15Gemcitabine 14Cyclophosphamide 13Radiotherapy 10Drug Therapy 9atezolizumab 8Platinum 7Ipilimumab 7Doxorubicin 7durvalumab 61,2-diaminocyclohexaneplatinum II citrate 6tremelimumab 5sodium thiosulfate 5Vinorelbine 5Radiotherapy, Intensity-Modulated 5Interleukin-2 5Chemotherapy, Adjuvant 5Cerebral Decortication 5sargramostim 4fludarabine 4defactinib 4aldesleukin 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3cediranib 3Photochemotherapy 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Surgery, Computer-Assisted × Clear all
NCT03760575 2025-12-04

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Abramson Cancer Center at Penn Medicine

Phase 1 Recruiting
20 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡